Vildagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vildagliptin: From Type 2 Diabetes to Classic Stiff Person Syndrome
One-Sentence Summary
Vildagliptin is a DPP-4 inhibitor used to lower blood glucose in type 2 diabetes. The SAHPRA records provided do not state an indication. The TxGNN model predicts it may be effective for classic stiff person syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (inferred from drug class and the literature; the SAHPRA records provided leave indication text blank) |
| Predicted New Indication | Classic stiff person syndrome |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Vildagliptin is a DPP-4 inhibitor that raises active GLP-1 and GIP and suppresses glucagon. Its efficacy in type 2 diabetes is well established, but nothing in the supplied data shows a mechanism for neurological benefit.
Stiff person syndrome is an autoimmune neurological disorder. It is often associated with anti-GAD65 antibodies and coexisting type 1 diabetes. This overlap with diabetes may explain why the knowledge graph links it to a diabetes drug. It is a network association, not a demonstrated pharmacological link. The very high score is more likely a graph-proximity effect than a real therapeutic signal.
The next four predictions (focal stiff limb syndrome, opsismodysplasia and two similar lipodystrophy-type conditions) show the same pattern. They are prediction-only, with no plausible DPP-4 mechanism in the data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 57/21.2/0061 | Vileptin Co 50/1 000 | Tablet |
| Reg. No. 57/21.2/0060 | Vileptin Co 50/850 | Tablet |
Both products are oral tablets. The strengths are consistent with fixed-dose vildagliptin–metformin combinations, though the record does not state this. Approved indication text and Essential Medicines List (EML) status are not available in the record.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no trials, no literature and no plausible mechanism in the supplied data. Nothing supports moving stiff person syndrome forward.
Other predictions in the pack:
- Type 1 diabetes mellitus (rank 10, score 99.37%) has the strongest evidence at L3, marked “Research Question”.
- It is supported by small human studies, including a glucagon counterregulation study (PMID 22855332), a randomized Ramadan adjunct trial (PMID 38057844), and rodent beta-cell studies.
- The rapamycin plus vildagliptin randomized trial (PMID 33124663) is confounded by the combination.
- The 50 registry trials matched to that term are mostly type 2 diabetes studies and should not be counted as type 1 evidence.
- Efficacy and safety with insulin, especially hypoglycaemia, remain unestablished.
To proceed, the following is needed:
- SAHPRA Professional Information (PI) warnings and contraindications. This is currently a blocking gap.
- Mechanism of action data from DrugBank, to enable mechanistic-link analysis.
- For stiff person syndrome, any clinical or mechanistic evidence at all. Without it, no further work is justified.
- If type 1 diabetes is pursued, a dedicated review of type 1-specific studies and a hypoglycaemia safety assessment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.